Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
freem
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Openai/6958caf9-648c-800e-9920-bac13abca047
(section)
Add languages
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Special pages
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== 你可以用兩句話收斂: ==== # 嚴謹版: 「高端(Medigen)於 2023 年透過 WHO C-TAP/MPP 提供 COVID-19 疫苗技術的全球非專屬授權;但目前公開資訊中尚未看到該疫苗技術已被第三方再授權量產的宣布。C-TAP 之後由 WHO 演進為 HTAP。」世界衛生組織<ref>{{cite web|title=世界衛生組織|url=https://www.who.int/initiatives/covid-19-technology-access-pool/medigen-license-to-c-tap|publisher=who.int|access-date=2026-01-04}}</ref> # 反駁點(針對原文最惡意的地方): 「說 ‘計畫收攤’ 和 ‘高端消失’ 都不符合 WHO 的公開資料。」世界衛生組織<ref>{{cite web|title=世界衛生組織|url=https://www.who.int/news/item/31-01-2024-who-introduces-the-health-technology-access-pool|publisher=who.int|access-date=2026-01-04}}</ref> 如果你要更進一步「追究:到底有沒有任何 sublicensee 使用高端技術」,就得找 MPP/WHO 是否曾發布 sublicense 公告,或 MPP 年報/專案報告有沒有提到「MVC-COV1901 的 sublicensing 進度」。我可以再幫你把這條線索往下挖(但先講在前面:公開資料不一定會把洽談中案件寫出來)。
Summary:
Please note that all contributions to freem are considered to be released under the Creative Commons Attribution-ShareAlike 4.0 (see
Freem:Copyrights
for details). If you do not want your writing to be edited mercilessly and redistributed at will, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource.
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)